A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 28, Issue 3-4, 1998, Pages 307-314

  Witzig, Thomas E ^a   Camoriano, John K ^b   Schroeder, Georgene ^a   Kurtin, Paul J ^a   Habermann, Thomas M ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Non Hodgkins lymphoma; ProMACE CytaBOM chemotherapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FEMALE; HUMAN; HYPERGLYCEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LUNG TOXICITY; MALE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031928945     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809092686     Document Type: Article

References (9)

1. McKelvey, E., Gottlieb, J., Wilson, H., Haut, A., Talley, R., Stephens, R., Lane, M., Gamble, J., Jones, S., Grozea, P., Gutterman, J., Coltman, C. Jr. and Moon, T. (1976). Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1484-1493.
2. Connors, J. and Klimo, P. (1988). MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Seminars in Hematology, 25, 41-46.
3. Dana, B., Dahlberg, S., Miller, T., Hartsock, R., Balcerzak, S., Coltman, C., Carden, J., Hartley, K. and Fisher, R. (1990). m-BACOD treatment for intermediate and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial. Journal of Clinical Oncology, 8, 1155-1162.
4. Longo, D., DeVita, V. Jr., Duffey, P., Wesley, M., Ihde, D., Hubbard, S., Gilliom, M., Jaffe, E., Cossman, J., Fisher, R. and Young, R. (1991). Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal of Clinical Oncology, 9, 25-38.
5. Skarin, A., Canellos, G., Rosenthal, D., Case D. Jr., MacIntyre, J., Pinkus, G., Moloney, W. and Frei, E. III (1983). Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). Journal of Clinical Oncology, 1, 91-98.
6. Fisher, R., Gaynor, E., Dahlberg, S., Oken, M., Grogan, T., Mize, E., Glick, J., Coltman C. Jr. and Miller, T. (1993). Comparison of a standard regimen (CHOP) with three intensive regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
7. Gaynor, E. and Fisher, R. (1995). Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? Oncology? 9, 1273-1279.
8. Gordon, L., Andersen, J., Habermann, T., Winter, J., Glick, J., Schilder, R. and Cassileth, P. (1996). Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. Journal of Clinical Oncology, 14, 1275-1281.
9. Shipp, M., Neuberg, D., Janicek, M., Canellos, G. and Shulman, L. (1995). High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Journal of Clinical Oncology, 13, 2916-2923.